| 摘要 |
<p>Abstract - 595458 Disclosed herein is a compound or a pharmaceutically acceptable salt thereof selected from the given formulaes, processes for their preparation, pharmaceutical compositions comprising said compounds and uses thereof in the treatment of HCV-associated disorders, such as HCV infection, liver cirrhosis, chronic liver disease, hepatocellular carcinoma, cryoglobulinaemia, non-Hodgkin's lymphoma, liver fibrosis and a suppressed innate intracellular immune response. Particularly preferred compounds include: (5R,8S)-7-[(2S)-2-{ [(2S)-2-cyclohexyl-2-({ [(2S)-1-isopropylpiperidin-2-yl]carbonyl} amino)acetyl]amino} -3,3-dimethylbutanoyl]-N-{ (1 R,2R)-2-ethyl-1-[(pyrrolidin-1-ylsulfonyl)carbamoyl]cyclopropyl} -10,10-dimethyl-7-azadispiro[3.0.4.1]decane-8-carboxamide; (5R,8S)-7-[(2S)-2-{ [(2S)-2-cyclohexyl-2-({ [(2S)-1-isopropylpiperidin-2-yl} carbonyl} amino)acetyl]amino} -3,3-dimethylbutanoyl]-10,10-dimethyl-N-{ (1R,2S)-1-[(pyrrolidin-1-ylsulfonyl)carbamoyl]-2-vinylcyclopropyl} -7-azadispiro[3.0.4.1]decane-8-carboxamide.</p> |
